Yun-chi Lu

Kaohsiung, KHQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Tumor-associated protease-activated anti-CD47 antibody precisely maintains phagocytic ability of macrophages with minimal effect on healthy tissue.

Tumor-associated protease-activated anti-CD47 antibody precisely maintains phagocytic ability of macrophages with minimal effect on healthy tissue.

Journal: Journal of translational medicine

Published: September 14, 2025

Protease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy.

Protease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy.

Journal: International journal of biological macromolecules

Published: February 17, 2025

Spatial-hindrance-based pro-Adalimumab prevents anti-idiotypic antibody interference in pharmacokinetic and therapeutic efficacy.

Spatial-hindrance-based pro-Adalimumab prevents anti-idiotypic antibody interference in pharmacokinetic and therapeutic efficacy.

Journal: Bioengineering & translational medicine

Published: October 14, 2024

Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice.

Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice.

Journal: Frontiers in immunology

Published: August 31, 2021

Correction: Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies.

Correction: Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies.

Journal: Chemical science

Published: July 07, 2021

Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies.

Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies.

Journal: Chemical science

Published: March 29, 2021

Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy.

Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy.

Journal: Scientific reports

Published: March 12, 2021

Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.

Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.

Journal: Journal of nanobiotechnology

Published: September 24, 2020

Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy.

Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy.

Journal: Scientific reports

Published: August 03, 2020

Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer.

Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer.

Journal: Journal of nanobiotechnology

Published: May 11, 2020

Ab locks for improving the selectivity and safety of antibody drugs.

Ab locks for improving the selectivity and safety of antibody drugs.

Journal: Journal of biomedical science

Published: February 11, 2020

Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.

Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.

Journal: Acta biomaterialia

Published: October 25, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026